The first product, developed from a new technological platform from Lesaffre that targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections.
Gnosis by Lesaffre (Marcq-En-Baroeul, France) introduceda phages-based ingredient line to help target specific pro-inflammatory or pathogenic bacteria in the gut and potentially enhance the gastrointestinal benefits of probiotics.
“Consumers recognize probiotics and how they support our digestive health and overall health,” said Philippe Caillat, Gnosis by Lesaffre’sglobal marketing director, in a press release. “That’s what pushed us to continue exploring solutions for targeted digestive disorders, such as abdominal pain, diarrhea, and gut flora restoration. Good gut health truly is the essence of a good life. We’re here to bring that to life with our new phages-based portfolio.”
The first product, developed from a new technological platform fromLesaffrethat targets the main drivers of pathogen—induced digestive issues—is intended to fight pathogenic bacteria responsible for serious infections such as E.coli, Salmonella, and Listeria.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.